课题基金 / 基金详情

Role of IL-33-innate lymphoid cells 2 (ILC2) pathway in endometriosis pathophysiology and therapeutic targeting

Role of IL-33-innate lymphoid cells 2 (ILC2) pathway in endometriosis pathophysiology and therapeutic targeting
IL-33-先天淋巴细胞 2 (ILC2) 通路在子宫内膜异位症病理生理学和治疗靶向中的作用
批准号：
478171
负责人：
Tayade Chandrakant
金额：
$66.6万
依托单位：
Queen's University (Kingston, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2023
资助国家：
加拿大
项目状态：
未结题
起止时间：
2023-03-01 至 2028-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=478171&lang=en
关键词：
Endometriosis Fibrosis Inflammation Innate Lymphoid Cells 2 Interleukin-33 Therapeutic Development Vascularization

项目摘要

项目成果

Tayade Chandrakant的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Endometriosis (EM) is a disease where normal lining of the uterus, called endometrium, grows outside on the organs (bowel, bladder, ovaries) in pelvic cavity. It is estimated to affect ~200 million women worldwide and more than 50% of them experience infe
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Unique extracellular vesicle signatures in the pathophysiology of endometriosis
Role of IL-33-innate lymphoid cells 2 (ILC2) pathway in endometriosis pathophysiology and therapeutic targeting.
Investigating the role of endocannabinoids in endometriosis pathophysiology and determine efficacy of cannabinoids as a novel therapeutic modality.
Therapeutic targeting of immune-inflammation pathway via IL23-IL17 axis in Endometriosis
海外基金